TY - JOUR
T1 - DAOA variants on diagnosis and response to treatment in patients with major depressive disorder and bipolar disorder
AU - Chiesa, A.
AU - Pae, Chi Un
AU - Porcelli, S.
AU - Han, C.
AU - Lee, S. J.
AU - Patkar, A. A.
AU - Park, M. H.
AU - Jun, T. Y.
AU - Serretti, A.
N1 - Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2012/2
Y1 - 2012/2
N2 - Objective: This study investigated whether selected D-amino acid oxidase activator (DAOA) gene single nucleotide polymorphisms (SNPs; rs3916966, rs3916967, rs2391191, rs3916968, rs7139958, rs9558571, rs778293) are associated with major depressive disorder (MDD) and bipolar disorder (BD), and whether they can predict clinical outcomes in Korean in-patients treated with antidepressants and mood stabilizers, respectively. Methods: In total, 145 patients with MDD, 132 patients with BD and 170 psychiatrically healthy controls were genotyped for the DAOA SNPs. Baseline and final clinical assessments included the Montgomery- Asberg Depression Rating Scale and Young Mania Rating Scale for patients with MDD and BD, respectively. Results: There was no association between DAOA SNP genotypes or alleles with diagnosis, clinical improvement, response rates or remission rates for MDD and BD. Haplotype analyses found no association with MDD or BD diagnosis or clinical outcomes. Conclusion: The findings suggest that the DAOA SNPs investigated may not affect MDD or BD phenotype, clinical symptoms or other clinical factors, and are unlikely to be involved in MDD or BD development and treatment outcomes. Given the study's limitations, further investigation should be carried out.
AB - Objective: This study investigated whether selected D-amino acid oxidase activator (DAOA) gene single nucleotide polymorphisms (SNPs; rs3916966, rs3916967, rs2391191, rs3916968, rs7139958, rs9558571, rs778293) are associated with major depressive disorder (MDD) and bipolar disorder (BD), and whether they can predict clinical outcomes in Korean in-patients treated with antidepressants and mood stabilizers, respectively. Methods: In total, 145 patients with MDD, 132 patients with BD and 170 psychiatrically healthy controls were genotyped for the DAOA SNPs. Baseline and final clinical assessments included the Montgomery- Asberg Depression Rating Scale and Young Mania Rating Scale for patients with MDD and BD, respectively. Results: There was no association between DAOA SNP genotypes or alleles with diagnosis, clinical improvement, response rates or remission rates for MDD and BD. Haplotype analyses found no association with MDD or BD diagnosis or clinical outcomes. Conclusion: The findings suggest that the DAOA SNPs investigated may not affect MDD or BD phenotype, clinical symptoms or other clinical factors, and are unlikely to be involved in MDD or BD development and treatment outcomes. Given the study's limitations, further investigation should be carried out.
KW - Bipolar disorder
KW - Clinical improvement
KW - D-amino acid oxidase activator (DAOA)
KW - Major depressive disorder
KW - Treatment response
UR - http://www.scopus.com/inward/record.url?scp=84863290878&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863290878&partnerID=8YFLogxK
U2 - 10.1177/147323001204000126
DO - 10.1177/147323001204000126
M3 - Article
C2 - 22429365
AN - SCOPUS:84863290878
VL - 40
SP - 258
EP - 265
JO - Journal of International Medical Research
JF - Journal of International Medical Research
SN - 0300-0605
IS - 1
ER -